NEUROPEPTIDES

Neuropeptides (1989) **14**, 285-292
© Longman Group UK Ltd 1989

Subject Index to Volumes 13/14

A

Accumbens nucleus *see* Nucleus accumbens
Acetylcholinesterase levels in the brain of pentylenetetrazol-kindled rats, **14**.197
Actinonin, protection of endogenous enkephalins from degradation by peptidases in human serum by, **13**.201
Adrenal medulla, bovine
  cholinergic receptor mediated secretion from, stimulation by neuropeptide Y of, **13**.35
  effects of angiotensin II on, **13**.121, **13**.243
  neuropeptides and other secretagogues in, effect on opioid metabolism of, **13**.243
Adrenaline (epinephrine)
  secretion from the bovine adrenal medulla of, stimulation by neuropeptide Y of, **13**.35
  secretion from bovine adrenal medullary cells of, effect of angiotensin II on, **13**.121
Adrenocorticotropic hormone (ACTH)
  development during continuous intracerebroventricular infusion in rats of tolerance to the behavioural effects of, and association with increased levels of β-endorphin in the hypothalamus, **14**.93
  ORG 2766 analogue of, role of opioid systems in the amygdala in the behavioural affects of, **14**.129
Alanyl aminopeptidase from human cerebral cortex, specificity of action on leu-enkephalin- and dynorphin-related peptides of, **13**.259
α-aminobutyric acid *see* GABA
Amygdala
  effect of cysteamine on somatostatin-like immunoreactivity in the rat brain following kindling of, **14**.11
  role of opioid systems in, in the behavioural effects of the ACTH analogue ORG 2766, **14**.129
Anesthetics, effect on the concentrations of cholecystokinin octapeptide sulfate-like immunoreactivity in rat brain regions of, **14**.225
Angiotensin II
  effects on cultured bovine adrenal medullary cells of, **13**.121, **13**.243
  stimulation of sympathetic output by direct spinal action of, **14**.21
Angiotensin converting enzyme, inhibition by N-terminal fragments of substance P of, **14**.213
Anorexia nervosa, involvement of cyclo(His-Pro) in, **14**.185
Antinociceptive effect(s)
  of caerulein, and interaction with morphine and opioid antagonists in the rat, **14**.263
  of [D-Arg^2, β-Ala^4]-dermorphin tetrapeptide, compared with that of morphine or pentazocine, **13**.83
  of intracerebrally administered dynorphin-B in mice, effect of bestatin on, **13**.277
  of morphine and substance P, reduction by intrathecal administration of 5,6- or 5,7-dihydroxytryptamine of, **13**.139
Aorta, rat thoracic, endothelium-independent relaxation and elevation of cyclic GMP in, caused by brain natriuretic peptide, **14**.161
Apomorphine, effect of, on cholecystokinin content via preferentially D1 or D2 dopamine receptor according to the regions of the rat brain, **13**.103
Arterial pressure
  effect of endothelin on, after systemic and central nervous system administration in the conscious rat, **14**.231
  effect of intrathecal administration of angiotensin II on, **14**.21
  see also Renin
Artial natriuretic factor
  cross-reaction with neurophysins of an antiserum to, in the hypothalamo-neurohypophyseal system of rat brain, **14**.137
  vasodilation caused by, comparison between effects of brain natriuretic peptide and, **14**.161

B

BC-197 (cyclic CCK analogue), antagonist effect of, on the potencies of CCK-8 and its analogue BOC(Nle^{28}; Nle^{31}) CCK_{27-33} on the self-stimulation behaviour, **13**.89
Behavioural effects/studies
  of adrenocorticotropic hormone, development of tolerance to, and association with increased hypothalamic levels of beta-endorphin, **14**.93
  of adrenocorticotropic hormone analog ORG 2766, role of

opioid systems in the amygdala in, **14**.129
of cholecystokinin octapeptide and its analogues on the self-stimulation behaviour, **13**.89
of cholecystokinin octapeptide-related peptides, **13**.107
of corticotropin-releasing factor, **13**.147
of insulin, **13**.79
Bestatin, effect of, on the antinociceptive and motor responses induced by intracerebrally administered dynorphin-B in mice, **13**.277
Bradykinin
binding sites in intact neuroblastoma-glioma cells in culture of, **14**.51
effect on opioid peptide metabolism in bovine adrenal medullary cells of, **13**.243
Brain
alanyl aminopeptidase from, specificity of action on leu-enkephalin- and dynorphin-related peptides of, **13**.259
atrial natriuretic factor in, distribution of, **14**.137
cholecystokinin levels in, and effect of apomorphine via preferentially D1 of D2 dopamine receptor, **13**.103
cholecystokinin octapeptide sulfate-like immunoreactivity levels in different regions of, following administration of anesthetics, **14**.225
[^{3}H]DAGO binding in, modulation via μ_1 interactions by substance P and SP fragments of, **13**.225
enkephalinase mRNA in, localization in the rat by in situ hybridization of, and comparison with immunohistochemical localization of the protein, **14**.77
iodinated-neuropeptide-Y binding sites in, **13**.23
neuronal and glial cultures from rat fetus, degradation of substance P by, **14**.31
neurotensin in microdissected nuclei of, in the lean and obese Zucker rats, **13**.1
neurotransmitter release in, selectivity of various opioid peptides towards delta-, kappa;, and mu-opioid receptors mediating presynaptic inhibition of, **14**.99
somatostatin binding in, effect of long-term haloperidol treatment on, **13**.157
tumours, expression of the preproenkephalin A gene in, a Northern and in situ hybridization study of, **13**.133
see also Cerebrospinal fluid; Intracerebroventricular administration; *and also individual brain regions*
Brain natriuretic peptide, endothelium-independent relaxation and elevation of cyclic GMP in rat thoracic aorta by, **14**.161
Bronchoconstrictor action of neuropeptide Y in isolated guinea-pig airways, **13**.215
Bulimia, involvement of cyclo(His-Pro) in, **14**.185

C

Caerulein, antinociception induced by, and interaction with morphine and opioid agonists in the rat, **14**.263
Calcitonin gene-related peptide
binding sites in mouse T-lymphocytes of, **14**.237
coronoray vasodilation induced by, in the anesthetized pig, **13**.95
increase in the rat in eosinophil chemotactic response to, after exposure to trypsin or guinea-pig lung particulate fraction, **13**.29
opioid control of the in vitro release of, from primary afferent fibres projecting in the rat cervical cord, **14**.151
Catecholamines, effect of cysteamine on levels of, and on electroencephalogram in the rat brain, **14**.1
Cerebrospinal fluid, somatostatin and beta-endorphin levels in, of nonmedicated and medicated patients with epileptic seizures, **13**.9
Ceruletide, a behavioural pharmacological study on intracerebroventricular administration of, **13**.107
Chemotactic eosinophil response to rat calcitonin gene-related peptide-1, after exposure to trypsin or guinea-pig lung particulate fraction, **13**.29
Chloral hydrate, effects of, on the concentrations of cholecystokinin octapeptide sulfate-like immunoreactivity in rat brain regions, **14**.225
Cholecystokinin
antinociceptive effects of, produced by separate yet overlapping mechanisms from those of opioids, **14**.263
effect of anesthetics on, in rat brain regions, **14**.225
effect of apomorphine on, via preferentially D1 or D2 dopamine receptor according to the regions of the rat brain, **13**.103
effect of infusion of quinolinic acid into rat striatum on, in striatal-nigral neuronal networks, **13**.71
interference in the thermoregulatory effect of exogenous and endogenous opioids by, **14**.85
levels in the central nervous system of, strain differences between normotensive Wistar-Kyoto and spontaneously hypertensive rats in, **14**.59
levels in the nucleus accumbens of, following 6-hydroxy-dopamine lesions of the ventral tegmental area and of the nucleus accumbens, **14**.71
potency on the self-stimulation behaviour in rats of, and of CCK-8 and its analogue BOC(Nle^{28};Nle^{31})CCK$_{27\text{-}33}$, **13**.89
regulation of [^{3H}]dopamine efflux from the rat nucleus accumbens by, **13**.43
-related peptides, a behavioural pharmacological study on intracerebroventricular administration of, **13**.107
-related peptides, isolation from the American cockroach of, **14**.145
Choline acetyltransferase levels in the brain of pentylene-tetrazol-kindled rats, **14**.197
Cholinergic receptor mediated secretion from the bovine adrenal medulla, stimulation by neuropeptide Y of, **13**.35
Chromaffin cells *see* Adrenal medulla, bovine
Corticotropin-releasing factor
intracerebroventricular injection of, behavioural and biochemical studies of the effects on the central nervous system of, **13**.147
stress-induced changes in hypothalamic mRNA for, glucocorticoid inhibition of, **14**.17
Cyclic GMP, elevation in rat thoracic aorta by brain natriuretic peptide of, **14**.161
Cyclo(His-Pro)
distribution of, in discrete rat hypothalamic nuclei, **13**.221
involvement in eating disorders of, **14**.85
radioimmunoassay of, in unextracted human plasma, **13**.65
Cysteamine
effect of, on levels of somatostatin-like immunoreactivity and on catecholamines and on electroencephalogram, **14**.1
following kindling of the amygdala, **14**.11
effect of, on the TSH-stimulated mitotic activity of rat thyroid follicular cells in vivo, **13**.171

D

DAGO ([D-Ala^2, MePhe^4, Gly-(ol)^5]enkephalin)

effect on the horizontal and vertical components of locomotor activity in mice of, **13**.235
effect on jejunal absorption of intracerebroventricular administration of, **14**.39
modulation by substance P and SP fragments of binding of, via μ_1 interactions in the mouse brain and spinal cord, **13**.225
selectivity towards delta, kappa- and mu-opioid receptors of, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99
Delta (δ) opioid receptors
analgesic effect of intrathecally injected agonists, involvement of opioid-induced presynaptic inhibition of CGRP-containing primary afferent fibres in, **14**.151
differential control of horizontal and vertical components of locomotor activity in mice by mu-opioid receptors and, **13**.235
selectivity of various opioid peptides towards, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99
Dependence *see* Physical dependence
Dermorphin
and related peptides in rat tissues, **13**.51
[D-Arg^2, β-Ala^4]-tetrapeptide of, physical dependence induced by, **13**.83
Dexamethasone inhibition of stress-induced changes in hypothalamic corticotropin-releasing factor mRNA and proenkephalin A mRNA, **14**.17
Digoxigenin-labeled oligodeoxyribonucleotide probe, simultaneous use with radiolabeled probe in hybridization histochemistry of, **13**.271
Dihydroxytryptamine, effect of intrathecal administration of, on morphine and substance P antinociceptive activity in the rat, **13**.139
Dopamine
effects of dopaminergic drugs on the levels of beta-endorphin-like immunoreactivity in rat hypothalamic nuclei, **13**.285
efflux from rat nucleus accumbens of, regulation by cholecystokinin of, **13**.43
levels in the rat brain of, effects of cysteamine on electroencephalogram and on, **14**.1
levels in the rat nucleus accumbens of, following 6-hydroxydopamine lesions of the ventral tegmental area and of the nucleus accumbens, **14**.71
presynaptic inhibition of release of, and selectivity of various opioid peptides towards delta-, kappa- and mu-opioid receptors, **14**.99
D1 and D2 receptors of, effect of apomorphine on cholecystokinin content via, according to the regions of the rat brain, **13**.103
turnover rate of, following intracerebroventricular administration of corticotropin-releasing factor in rats, **13**.147
DPDPE ([D-Pen^2, D-Pen^5]enkephalin)
effect on the horizontal and vertical components of locomotor activity in mice of, **13**.235
selectivity towards delta-, kappa- and mu-opioid receptors of, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99
Dynorphin
antinociceptive and motor responses to intracerebral administration in mice of, efects of bestatin on, **13**.277
hippocampal levels of, in spontaneously hypertensive rats, **13**.197
induction of hypothermia by, **14**.45
measurement and chromatographic characterization of, in the guinea-pig ileum, **13**.207
-related peptides, action of human brain alanyl aminopeptidase on, **13**.259
-releated peptides, selectivity towards delta-, kappa- and mu-opioid receptors of, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99

E

Eating and feeding
involvement of cyclo(His-Pro) in human disorders of, **14**.185
radioimmunoassay to determine changes in plasma neuropeptide-Y levels in awake dogs following, **14**.209
Electroencephalogram, effect of cysteamine on, in the rat brain, **14**.1
Endopeptidase-24.11 *see* Enkephalinase
α-neo-endorphin, measurement and chromatographic characterization of, in the guinea-pig ileum, **13**.207
β-endorphin
distribution in the infundibular nucleus of the sheep of, **14**.121
levels of, in cerebrospinal fluid of nonmedicated and medicated patients with epileptic seizures, **13**.9
levels of, in discrete rat hypothalamic nuclei, regulation by monoamines of, **13**.285
levels of, in the rat hypothalamus, and association with development of tolerance to the behavioural effects of adrenocorticotropic hormone during continuous intracerebroventricular infusion, **14**.93
Endothelin, hemodynamic effects of, after systemic and central nervous system administration in the conscious rat, **14**.231
Enkephalin(s)
generation of immunoreactive peptides by peptic digestion of rat plasma proteins, **13**.17
protection by actinonin from degradation by human serum peptidases of, **13**.201
see also Enkephalinase; Leucine-enkephalin; Methionine-enkephalin; Preproenkephalin A; Proenkephalin A
Enkephalinase
involvement in degradation of substance P by glioma cells of, **14**.177
localization in the rat brain by in situ hybridization of mRNA encoding, and comparison with immunohistochemical localization of the protein, **14**.77
Eosinophils, chemotactic response of, to rat calcitonin gene-related peptide-1, after exposure to trypsin or guinea-pig lung particulate fraction, **13**.29
Epilepsy
somatostatin and beta-endorphin levels in cerebrospinal fluid of nonmedicated and medicated patients with, **13.9**
see also Kindling
Epinephrine *see* Adrenaline

F

Feeding *see* Eating and feeding
FLFQPQRFamide, electrophysiological effects on cultured mouse spinal cord neurons of, **14**.253

G

GABA (gamma-aminobutyric acid)

effect of, on quinolinic acid-induced increases in cholecystokinin octapeptide sulfate-like immunoreactivity in the striatum and substantia nigra of the rat, **13**.71
levels of, in the brain of pentylenetetrazol-kindled rats, **14**.197
Gastrin-related neuropeptides, isolation from the American cockroach of, **14**.145
Glial cells
degradation of substance P by, cultured from rat fetal brain, **14**.31
glioma cells
bradykinin binding sites in, **14**.51
expression of the preproenkephalin A gene in, **13**.133
involvement of endopeptidase-24.11 in degradation of substance P by, **14**.177
Glucocorticoid inhibition of stress-induced changes in hypothalamic corticotropin-releasing factor mRNA and proenkephalin A mRNA, **14**.17
Glyburide, increase in insulin and insulin-like growth factor binding to neuroblastoma cells following treatment with, **14**.171

H

Habenula, co-expression in the rat of neurokinin B and substance P genes in a subset of neurons in, **13**.165
Habituation of the spinal polysynaptic reflex responses, modification by naloxone and role of opioid peptides in, **14**.115
Haloperidol
effect of, on quinolinic acid-induced increases in cholecystokinin octapeptide sulfate-like immunoreactivity in the striatum and substantia nigra of the rat, **13**.71
effect of long-term treatment with, on somatostatin binding in the rat brain, **13**.157
Halothane, effects of, on the concentrations of cholecystokinin octapeptide sulfate-like immunoreactivity in rat brain regions, **14**.225
Heart
coronary vasodilation induced by calcitonin gene-related peptide in the anaesthetized pig, **13**.95
distribution of atrial natriuretic factor in, **14**.137
rate
effect of endothelin on, after systemic and central nervous system administration in the rat, **14**.231
effect of intrathecal administration of angiotensin II on, **14**.21
effect of intrathecal administration of vasoactive intestinal peptide on mediation by a non-central nervous system mechanism of, **14**.243
Helodermin, effect on thyroid hormone secretion in the mouse of, **13**.59
Hippocampus, low levels of dynorphin in, in spontaneously hypertensive rats, **13**.197
Histidyl proline diketopiperazine *see* Cyclo(His-Pro)
Hybridization histochemistry
localization of enkephalinase mRNA in the rat brain by, and comparison with immunohistochemical localization of the protein, **14**.77
simultaneous use of digoxigenin- and radiolabeled oligodeoxyribonucleotide probes for, **13**.271
6-hydroxydopamine, levels of cholecystokinin and dopamine in the nucleus accumbens following injection into the ventral tegmental area and nucleus accumbens of, **14**.71
Hypertensive rats, spontaneously
low hippocampal dynorphin A(1-8) immunoreactivity in, **13**.197
strain differences in CNS cholecystokinin concentrations between normotensive Wistar-Kyoto rats and, **14**.59
Hyperthermia, stress-and opioid-induced, interference by cholecystokinin in the effects of, **14**.85
Hypothalamus
corticotropin-releasing factor mRNA and proenkephalin A mRNA levels in, glucocorticoid inhibition of stress-induced changes in, **14**.17
cross-reaction of an atrial natriuretic factor antiserum with neurophysins in, **14**.37
distribution of cyclo(His-Pro) in discrete nuclei of, **13**.221
β-endorphin levels in
increases in, and association with the development of tolerance to the behavioural effects of adrenocorticotropic hormone during continuous intracerebroventricular infusion in rats, **14**.93
monoaminergic regulation of, **13**.285
thyrotropin-releasing factor levels in
distribution in discrete nuclei of, **13**.221
effect of pyroglutamyl peptidase II inhibition on, **14**.191
Hypothermia, induction by prodynorphin-derived peptides of, **14**.45

I

Ileum
blockade by omega-conotoxin GVIA of neuronal mechanisms in, **13**.253
measurement and chromatographic characterization of prodynorphin-derived peptides in, in the guinea-pig, **13**.207
Inflammation, substance P-induced hydrolysis of inositol phospholipids in rat skin in an in vivo model of, **13**.191
Infundibular nucleus, distribution in the sheep of neuropeptides in, **14**.121
Inositol phospholipids
metabolism in the rat parotid gland of, importance of the presence of the N-terminal tripeptide of substance P for the stimulation of, **13**.175
substance P-induced hydrolysis in the rat skin of, **13**.191
see also Phosphatidylinositol metabolism
Insulin
increase in neuroblastoma cells in mRNA for and binding of, following treatment with glyburide, **14**.171
intracerebroventricular administration of, and passive avoidance response in rats, **13**.79
Insulin-like growth factor increase in neuroblastoma cells in mRNA for and binding of, following treatment with glyburide, **14**.171
Intracerebroventricular administration
of adrenocorticotropic hormone, development of tolerance to behavioural effects during, and association with increased hypothalamic levels of beta-endorphin, **14**.93
of cholecystokinin analogue BC-197, effect on the self-stimulation behaviour of, **13**.89
of cholecystokinin-8-related peptides, **13**.107
of corticotropin-releasing factor, effects on the central nervous system of, **13**.147
of endothelin, hemodynamic effects of, **14**.231

of insulin, effect on the passive avoidance response in rats of, **13**.79
of selective opiate agonists, effect on jejunal absorption of, **14**.39

J

Jejunum, effect of intracerebroventricular administration of selective opiate agonists on absorption by, **14**.39

K

Kappa (κ) opioid receptors, selectivity of various opioid peptides towards, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99
Kindling
of the amygdala, effect of cysteamine on somatostatin-like immunoreactivity in the rat brain following, **14**.11
with pentylenetetrazol, levels of somatostatin, neuropeptide Y, GABA and cholinergic enzymes in the brain of rats following, **14**.197

L

Learning
arginine vasopressin retards spatial alternation learing, **14**.219
intracerebroventricular administration of insulin attenuates retrieval of a passive avoidance response in rats, **13**. 79
Leucine-enkephalin
generation of low molecular weight immunoreactive peptides by peptic digestion of rat plasma proteins, **13**.17
radioimmunoassay of, after protection by actinonin from degradation by human serum peptidases, **13**.201
-related peptides, action of human brain alanyl amino-peptidase on, **13**.259
Leucosulfakinins, isolation and structure of two gastrin/CCK-like neuropeptides from the American cockroach homologous to, **14**.145
Locomotor activity
differential control by mu and delta opioid receptors of the horizontal and vertical components of, **13**.235
effect of administration of ACTH analog ORG 2766 on, role of opioid systems in the amygdala in, **14**.129
effect of administration of thyrotropin-releasing hormone analogue CG3703 on, **14**.65
effect of intracerebrally administered dynorphin-B in mice on, **13**.277
effect of intracerebroventricularly administered cholecystokinin-8-related peptides on, **13**.107
effect of intracerebroventricularly administered corticotropin-releasing factor on, **13**.147
Lung(s)
angiotensin converting enzyme from, inhibition by N-terminal fragments of substance P of, **14**.213
bronchoconstrictor action of neuropeptide Y on, **13**.215
exposure of rat calcitonin gene-related peptide-1 to a guinea-pig particulate fraction of, and eosinophil chemotactic response, **13**.29
Lymphocytes(s)
calcitonin gene-related peptide receptor in mouse T-cells, **14**.237
enhancement by somatostatin of natural killer activity of, **13**.75

M

Mesotocin, isolation from goose neurohypophysis of neurosecretory granules containing, **13**.187
Methionine-enkephalin
generation of a low molecular weight immunoreactive peptide by peptic digestion of rat plasma proteins, **13**.17
treatment of the rat supraoptic nucleus with, sex-specific effects on vasopressin immunoreactivity of, **13**.115
Monoamines, regulation of beta-endorphin levels in discrete rat hypothalamic nuclei by, **13**.285
Morphine
antinociceptive effect in the rat of and caerulein-induced antinociception, **14**.263
reduction of, by intrathecal administration of 5,6- or 5,7-dihydroxytryptamine, **13**.139
physical dependence induced by, **13**.83
thermoregulatory effects of, interference by cholecystokinin in, **14**.85
MSEL-neurophysins, isolation from goose neurohypophysis of neurosecretory granules containing, **13**.187
Mu (μ) opioid receptors
analgesic effect of intrathecally injected agonists, involvement of opioid-induced presynaptic inhibition of CGRP-containing primary afferent fibres in, **14**.151
differential control of horizontal and vertical components of locomotor activity in mice by delta opioid receptors and, **13**.235
modulation of [^{3}H]DAGO binding by substance P and SP fragments via interactions with, in the mouse brain and spinal cord, **13**.225
selectivity of various opioid peptides towards, and presynaptic inhibition of neurotransmitter release in the brain, **14**.99

N

Naloxone
effect on caerulein-induced antinociception of, **14**.263
modification of habituation and dehabituation of the spinal polsynaptic reflex responses by, **14**.115
treatment of the rat supraoptic nucleus with met-enkephalin and, sex-specific effects on vasopressin immunoreactivity of, **13**.115
Natural killer activity of human lymphocytes, enhancement by somatostatin of, **13**.75
Neural lobes, rat, oxytocin stimulation of oxytocin release from isolated nerve terminals of, **14**.269
Neuroblastoma
-glioma cells in culture, bradykinin binding sites in, **14**.51
increase in insulin and insulin-like growth factor binding to, following treatment with glyburide, **14**.171
Neurohypophysis
cross-reaction of an atrial natriuretic factor antiserum with neurophysins in, **14**.137
isolation of neurosecretory granules containing vasotocin, mesotocin, MSEL- and VLDV-neurophysins from, **13**.187
Neurokinin(s)
A, structure-activity studies of, **13**.263
B, co-expression with substance P gene in a subset of neurons in the rat habenula of the gene for, **13**.165
receptors for
interactions of substance P and related peptides with, **14**.275

selective agonists for, and chemical modifications suitable for protecting the peptides from degradation, **13**.263
Neuronal cells
degradation of substance P by, cultured from rat fetal brain, **14**.31
electrophysiological effects of FLFQPQRFamide on, cultured from mouse spinal cord, **14**.253
Neuropeptide Y
bronchoconstrictor action of, in isolated guinea-pig airways, **13**.215
distribution in the infundibular nucleus of the sheep of, **14**.121
effect on plasma renin activity in the anaesthetized cat of, **14**.111
iodinated binding sites of, autoradiographic study in the rat brain of, **13**.23
levels of, in the brain of pentylenetrazol-kindled rats, **14**.197
postprandial changes in plasma levels of, radioimmunossay to determine, **14**.209
stimulation of cholinergic receptor mediated secretion from the bovine adrenal medulla by, **13**.35
Neurophysins, cross-reaction of an atrial natriuretic factor antiserum with, in the hypothalamo-neurohypophysial system of rat brain, **14**.137
Neurotensin
distribution in the infundibular nucleus of the sheep of, **14**.121
distribution in microdissected brain nuclei and in the pituitary of the lean and obese Zucker rats of, **13**.1
effect on opioid peptide metabolism in bovine adrenal medullary cells of, **13**.243
Norepinephrine (noradrenaline)
effect of cysteamine on levels of, and on electroencephalogram in the rat brain, **14**.1
effect of noradrenergic drugs on the levels of beta-endorphin-like immunoreactivity in rat hypothalamic nuclei, **13**.285
presynaptic inhibition of release of, and selectivity of various opioid peptides towards delta-, kappa- and mu-opioid receptors, **14**.99
secretion from bovine adrenal medulla of, stimulation by neuropeptide Y of, **13**.35
secretion from bovine adrenal medullary cells of, effect of angiotensin II on, **13**.121
turnover rate of, following intracerebroventricular injection of corticotropin-releasing factor, **13**.147
Nucleus accumbens
cholecystokinin and dopamine levels in, following 6-hydroxydopamine lesions of the ventral tegmental area and of the nucleus accumbens, **14**.71
cholecystokinin-facilitated [^{3}H]dopamine efflux from, in the rat, **13**.43

O

Obesity and levels of neurotensin in microdissected brain nuclei and in the pituitary of Zucker rats, **13**.1
Oligodeoxyribonucleotide probes, digoxigenin- and radiolabeled, simultaneous use for hybridization histochemistry of, **13**.271
Omega-conotoxin GVIA, blockage of neuronal mechanisms in rat ileum by, **13**.253
ORG 2766 (ACTH analogue), role of opioid systems in the amygdala in the behavioural effects of, **14**.129
Oxytocin-stimulation of oxytocin release from isolated nerve terminals of rat neural lobes, **14**.269

P

Panic disorder, somatostatin and beta-endorphin levels in cerebrospinal fluid of patients with, **13**.9
Parotid gland, phosphatidylinositol metabolism in, importance of the presence of the N-terminal tripeptide of substance P for the stimulation of, **13**.175
Passive avoidance response, effect in rats of intracerebroventricular administration of insulin on, **13**.79
Pentazocine, physical dependence induced by, **13**.83
Pentobarbital, effects of, on the concentrations of cholecystokinin octapeptide sulfate-like immunoreactivity in rat brain regions, **14**.225
Pentylenetetrazol-kindled rats, somatostatin, neuropeptide Y, GABA and cholinergic enzymes in the brain of, **14**.197
Peptic digestion of rat plasma proteins, generation of low molecular weight enkephalin-immunoreactive peptides by, **13**.17
Peptidases, human serum, protection by actinonin of enkephalins from degradation by, **13**.201
Perisulfakinin, isolation from the American cockroach of, **14**.145
Phosphatidylinositol metabolism
in cultured bovine adrenal medullary cells, effect of angiotensin II on, **13**.121
in the rat parotid gland, importance of the presence of the N-terminal tripeptide of substance P for the stimulation of, **13**.175
Phospholipases C and D, activation by substance P of, in the metabolism of phosphatidylinositol in the rat parotid gland, and importance of the N-terminal tripeptide of substance P, **13**.175
Physical dependence induced by [D-Arg^2, β-Ala^4] -dermorphin tetrapeptide, **13**.83
Pituitary gland
neurotensin in, in the lean and obese Zucker rats, **13**.1 *see also* Neurohypophysis
Preproenkephalin A gene, expression in tumor cells and brain glioma of, a Northern and in situ hybridization study of, **13**.133
Prodynorphin-derived peptides
induction of hypothermia by, **14**.45
measurement and chromatographic characterization of, in the guinea-pig ileum, **13**.207
Proenkephalin A, glucocorticoid inhibition of stress-induced changes in hypothalamic mRNA for, **14**.17
Prostaglandin E_1, effect on jejunal absorption of, **14**.39
Pyroglutamyl peptidase II, increase in recovery of thyrotropin-releasing hormone released from rat brain slices following inhibition of, **14**.191

Q

Quinolinic acid, infusion into rat striatum of, and cholecystokinin system in striatal-nigral neuronal networks, **13**.71

R

Radioimmunoassay
of cyclo(His-Pro) in unextracted human plasma, **13**.65
to determine postprandial changes in plasma neuropeptide Y levels in awake dogs, **14**.209
of enkephalins, protected by actinonin from degradation by human serum peptidases, **13**.201
Renin, effect of neuropeptide Y on plasma activity of, **14**.111

S

Seizures *see* Epilepsy; Kindling
Self-stimulation behaviour, intracranial, similar potencies of CCK-8 and its analogue BOC(Nle^{28};Nle^{31})CCK$_{27-33}$ on, **13**.89
Sex-specific effects of met-enkephalin treatment on vasopressin immunoreactivity in the rat supraoptic nucleus, **13**.115
Skin, substance P-induced hydrolysis of inositol phospholipids in, in an in vivo model of inflammation, **13**.191
Somatostatin
binding in the rat brain of, effect of long-term haloperidol treatment on, **13**.157
distribution in the infundibular nucleus of the sheep of, **14**.121
enhancement of human lymphocyte natural killer activity by, **13**.75
levels of
in brain of pentylenetetrazol-kindled rats, **14**.197
in cerebrospinal fluid of nonmedicated and medicated patients with epileptic seizures, **13**.9
effect of cysteamine on, and on catecholamines and on electroencephalogram, **14**.1
effect of cysteamine on, following kindling of the amygdala, **14**.11
Spinal cord
cultured mouse neurons from, electrophysiological effects of FLFQPQRFamide on, **14**.253
[^{3}H]DAGO binding in, modulation by substance P and SP fragments via μ_1 interactions of, **13**.225
habituation of polysynaptic reflex responses in, modification by naloxone of and role of opioid peptides in, **14**.115
in vitro release of CGRP from primary afferent fibres projecting in, opioid control of, **14**.151
intrathecal injection
of angiotensin II, and sympathetic output, **14**.21
of 5,6- or 5,7-dihydroxytryptamine, and morphine and substance P antinociceptive activity in the rat, **13**.139
of vasoactive intestinal peptide, mediation by a non-central nervous system mechanism of cardioacceleration provoked by, **14**.243
see also Cerebrospinal fluid
Stress
behaviour enhanced by, and effects of intracerebroventricularly injected corticotropin-releasing factor on the central nervous system, **13**.147
changes in hypothalamic corticotropin-releasing factor mRNA and proenkephalin A mRNA induced by, glucocorticoid inhibition of, **14**.17
hyperthermia induced by, effect of cholecystokinin on, **14**.85
Striatum
angiotensin converting enzyme from, inhibition by N-terminal fragments of substance P of, **14**.213
[^{3}H]dopamine efflux from, effect in the rat of cholecystokinin on, **13**.43
infusion in the rat of quinolinic acid into, and cholecystokinin system in striatal-nigral neuronal networks, **13**.71
Substance P
antinociceptive effect in the rat of, reduction by intrathecal administration of 5,6- or 5,7-dihydroxytryptamine of, **13**.139
binding of, on a NK-1 system in the rat brain, **14**.275
degradation by glioma cells of, involvement of endopeptidase-24.11 in, **14**.177
degradation of, by neuronal and glial cells cultured from rat fetal brain and their membranes, **14**.31
gene coding for, co-expression with neurokinin B gene in a subset of neurons in the rat habenula of, **13**.165
induction of hydrolysis of inositol phospholipids in rat skin by, in an in vivo model of inflammation, **13**.191
modulation of [^{3}H]DAGO binding by, in the mouse brain and spinal cord via μ_1 interactions, **13**.225
N-terminal fragment(s) of
importance for the stimulation of phosphatidylinositol metabolism in the rat parotid gland of, **13**.175
inhibition of angiotensin converting enzyme by, **14**.213
primary amino acid sequence in the guinea-pig of, **14**.105
Substantia nigra
cholecystokinin system in neuronal networks of, infusion of quinolinic acid into rat striatium, **13**.71
localization in the rat by in situ hybridization of enkephalinase mRNA in, and comparison with immunohistochemical localization of the protein, **14**.77
Supraoptic nucleus
distribution of atrial natriuretic factor in, **14**.137
vasopressin immunoreactivity in, sex-specific effects of met-enkephalin treatment on, **13**.115
Sympathetic nervous system
involvement of, in opioid-induced jejunal absorption, **14**.39
stimulation by direct spinal action of angiotensin II of, **14**.21

T

T lymphocytes, calcitonin gene-related peptide receptor in, **14**.237
Thermoregulation *see* Hyperthermia; Hypothermia
Thyroid gland
hormone secretion by, effects in the mouse of VIP and helodermin on, **13**.59
TSH-stimulated mitotic activity of follicular cells of, effect in the rat of cysteamine on, **13**.171
Thyrotropin-releasing hormone
CG3703 analogue of, effect on locomotion in the rat of the administration of, **14**.65
distribution in discrete rat hypothalamic nuclei of, **13**.221
effect of pyroglutamyl peptidase II inhibition on the recovery of, released from rat brain slices, **14**.191
Tryptic digestion of rat calcitonin gene-related peptide-1, effect on eosinophil chemotactic response of, **13**.29
Tumour(s) *see* Glioma; Neuroblastoma

V

Vasoactive intestinal peptide (VIP)
cardioacceleration provoked by intrathecal administration of, mediation by a non-central nervous system mechanism of, **14**.243
effect on thyroid hormone secretion in the mouse of, **13**.59
Vasodilation
coronory, induced by calcitonin gene-related peptide in the anaesthetized pig, **13**.95
of rat thoracic aorta, induced by brain natriuretic peptide, **14**.161
Vasopressin
effects of, on release of oxytocin and vasopressin from isolated nerve terminals of rat neural lobes, **14**.269
immunoreactivity in the rat supraoptic nucleus of, sex-specific effects of met-enkephalin on, **13**.115
retardation of spatial alternation learning by, **14**.219
Vasotocin, isolation from goose neurohypophysis of neuroscretory granules containing, **13**.187
Ventral tegmental area, 6-hydroxydopamine lesions of, levels of cholecystokinin and dopamine in the nucleus accumbens following, **14**.71
VLDV-neurophysins, isolation from the goose neurohypophysis of neurosecretory granules containing, **13**.187

NEUROPEPTIDES

Neuropeptides (1989) **14**, 293-295
© Longman Group UK Ltd 1989

Author Index to Volumes 13/14

A

ACHER, R., **13**.187
AHRÉN, B., **13**.59
ALLARD, M., **14**.253
ALLESCHER, H.-D., **13**.253
AMICHE, M., **13**.51
ANDREWS, P.V., **13**.191
ANTONOPOULOS, J., **14**.121
ARILLA, E., **13**.157
ARISAWA, M., **14**.237
ASAI, M., **14**.115
ASSAI, M., **14**.191

B

BALASUBRAMANIAM, A., **14**.209
BATTISTINI, N., **13**.23
BAZZANI, C., **14**.93
BEAL, M.F., **14**.197
BECK, B., **13**.1
BENABID, A.L., **13**.133
BENCHEKROUN, M.T., **13**.215
BENEDEK, G., **14**.85
BENOLIEL, J.J., **14**.151
BERNSTEIN, H.-G., **13**.79
BERTOLINI, A., **14**.93
BESSON, J.M., **14**.151
BIANCHI, B.R., **13**.43
BLANCO, E., **13**.115
BOMMER, M., **13**.243
BOURGOIN, S., **14**.151
BROWN, D.R., **14**.39
BUNN, S.J., **13**.121
BURGUNDER, J.-M., **13**.165
BURLET, A., **13**.1
BURLET, C., **13**.1

C

CADIEUX, A., **13**.215
CALZÀ, L., **13**.23
CANDELETTI, S., **14**.45
CARAYON, A., **14**.151
CARRETERO, J., **13**.115
CAVICCHINI, E., **14**.45
CESSELIN, F., **14**.151
CHAFFANET, M., **13**.133
CHAKI, K., **13**.83
CHARLI, J.-L., **14**.191
CHAUVET, J., **13**.187
CHAUVET, M.-T., **13**.187
CHAUVIN, C., **13**.133
CISNEROS, M., **14**.191
CLARKE, K.A., **14**.65
CLASSEN, M., **13**.253
COLAS, B., **13**.157
CORDER, R., **14**.111
COSTENTIN, J., **13**.235

D

DAVALL, E.J., **14**.219
DAYAL, R., **14**.209
DE BELLEROCHE, J., **14**.263
DELFOUR, A., **13**.51
DE WITTE, PH., **13**.89
DION, S., **13**.263
DOURMAP, N., **13**.235
DRAPEAU, G., **13**.263, **14**.275
DREUX, C., **13**.175

E

ENDO, S., **14**.31, **14**.177

F

FACCHINETTI, F., **14**.93
FALKE, N., **14**.269
FERNÁNDEZ-GUARDIOLA, A., **14**.115
FERRI, S., **14**.45
FEUERSTEIN, G., **14**.231
FISCHER, J.E., **14**.209
FISCUS, R.R., **14**.161
FOOTE, A.M., **13**.133
FOURNIER, A., **13**.215
FRANKHUYZEN, A.L., **14**.99
FRYCZAK, J., **13**.171
FUKAHORI, M., **13**.285
FUKAMAUCHI, F., **13**.103
FUKUI, K., **14**.137

G

GAUTHIER, S., **14**.21
GEOFFRE, S., **14**.253
GIARDINO, L., **13**.23
GIBBS, D.M., **14**.137
GIBSON, A.M., **13**.259
GRASSI, J., **13**.51
GREENWALD, S.E., **13**.95
GUILLEMETTE, G., **14**.275
GÜNTHER, O., **13**.79
GUZMAN, A., **14**.253

H

HAGINO, Y., **13**.107
HAMON, M., **14**.151
HARBUZ, M.S., **14**.17
HAYNES, L.W., **13**.29
HAZATO, T., **13**.201
HEDNER, P., **13**.59
HEIDBREDER, CH., **13**.89
HELME, R.D., **13**.191
HENRY, J.L., **14**.21, **14**.243
HERZ, A., **13**.243
HEXUM, T.D., **13**.35
HILTON, C.W., **13**.65
HOGENBLOOM, F., **14**.99
HYTTINEN, J.-M., **14**.11

I

IGARASHI, Y., 14.71
IIZUKA, R., 13.107
IKEDA, M., 13.277
IMHOFF, V., 13.175
INGENITO, A.J., 13.197
ISHII, S., 14.31, 14.177
ITOH, M., 13.285

J

JARROTT, B., 14.59
JORDAN, C.C., 14.263
JOSEPH-BRAVO, P., 14.191
JOUSMÄKI, V., 14.1.

K

KANEKO, T., 13.277
KAPÁS, L., 14.85
KARAMANDLIS, A.N., 14.121
KATO, T., 13.71, 14.225
KAWAMURA, S., 13.83
KAWASAKI, H., 13.285
KAYA, K., 13.201
KHALIL, Z., 13.191
KIM, D.C., 13.225
KISARA, K., 13.83
KISO, Y., 13.277
KITAGAWA, K., 13.277
KROTEWICZ, M., 13.171
KRUMINS, S.A., 13.225
KUSHIMA, Y., 14.225

L

LAINÉ, M., 13.133
LARSON, A.A., 13.225
LAUFFART, B., 13.259
LEE, R.T.W., 14.51
LEGENDRE, P., 14.253
LEÓN-OLEA, M., 14.115
LEPOLA, U., 13.9
LeROITH, D., 14.171
LEVER, M.J., 13.95
LÉVY, B., 13.187
LEWINSKI, A., 13.171
LEWIS, S.J., 14.59
LI, S.J., 13.197
LIGHTMAN, S.L., 14.17
LINDBERG, I., 13.17
LIVETT, B.G., 14.213
LOLAIT, S.J., 14.51
LOMBARD, M.C., 14.151
LOPEZ-RUIZ, M.P., 13.157
LOWRY, P.J., 14.111

M

McDANIEL, W.F., 14.219
McDERMOTT, J.R., 13.259
McFADDEN, D.W., 14.209
MacINTYRE, I., 13.95
MALFROY, B., 14.77
MANLEY, H.C., 13.29
MÄNNISTÖ, P.T., 14.197
MANTLE, D., 13.259
MARLEY, P.D., 13.121
MARRAMA, D., 14.93
MARRAMA, P., 13.23
MATSUZAKI, I., 13.147
MAUBORGNE, A., 14.151
MENDELSOHN, F.A.O., 14.213
MENDEZ, M., 14.191
MICHAEL-TITUS, A., 13.235
MICHALOUDI, H., 14.121
MOR, A., 13.51
MOREAU, J., 14.77
MOROJI, T., 13.107, 13.147
MORRIS, H.R., 13.95
MULDER, A.H., 14.99
MULLER, J.-M., 14.51
MURPHY, R., 13.207, 14.105

N

NAKAGAWA, T., 14.225
NAKAJIMA, S., 13.201
NAKAZAWA, T., 13.277
NEUWELT, E.A., 14.137
NICOLAS, J.-P. 13.1
NICOLAS, P., 13.51
NILAVER, G., 14.137
NISSOU, M.F., 13.133
NOHTOMI, A., 13.285
NUSSBAUM, M.S., 14.209

O

OH-HASHI, Y., 14.225
OTA, A., 14.171

P

PÄÄKKÖNEN, A., 14.1
PAPADOPOULOS, G.C., 14.121
PARCHI, P., 13.23
PARTANEN, J., 14.1
PAWLIKOWSKI, M., 13.75, 13.171
PELLICER, F., 14.115
PENKE, B., 14.85
PEREZ-OSO, E., 13.157
PESTELLINI, V., 13.263
PITKÄNEN, A., 13.9, 14.1, 14.11, 14.197
POGGIOLI, R., 14.93
POHL, M., 14.151
POLLARD, H., 14.77
PRADELLES, P., 13.51
PRASAD, C., 13.65, 14.185

Q

QUITO, F.L., 14.39

R

RAMAGE, A.G., 14.111
RATTRAY, M., 14.263
REGOLI, D., 13.263, 14.275
REISER, M., 13.79
RHALEB, N.-E., 13.263
RIEKKINEN, P.J., 13.9, 14.1, 14.11, 14.197
RIESCO, J.M., 13.115
ROCHFORD, J., 14.243
RODRIGUEZ, F.D., 13.139
RODRIGUEZ, R.E., 13.139
ROGERS, D., 13.65, 14.185
ROGERSON, F.M., 14.213
ROLLANDY, I., 13.175
ROQUES, B.P., 13.89
ROSENBAUM, L.C., 14.137
ROSENKRANZ, R.T., 14.185
ROSSIGNOL, B., 13.175
ROST, N., 13.133
ROUILLÉ, Y., 13.187
ROUISSI, N., 13.263
ROVERO, P., 13.263
RUDNICKI, N., 14.209
RUSSETT, L.R., 13.35

S

SAGAN, S., 13.51
ST-PIERRE, S., 13.215
SAKURADA, S., 13.83
SAKURADA, T., 13.83
SAMSON, W.K., 14.137
SÀNCHEZ, F., 13.115
SÁNCHEZ-ALVAREZ, M., 14.115
SASAKI, Y., 13.83
SATO, T., 13.83
SCANLON, D., 14.213
SCHUSDZIARRA, V., 13.253
SCHWARTZ, J.C., 14.77
SCHWARZBERG, H., 13.79
SEWERYNEK, E., 13.171
SEYBOLD, V.S., 13.225
SHEN, F.-S., 13.17
SHEN-ORR, Z., 14.171
SHIBUYA, H., 13.103
SHULKES, A., 14.59
SIMMONNET, G., 14.253
SIRÉN, A.-L., 14.231
SIRVIÖ, J., 14.1, 14.197
SPAMPINATO, S., 14.45
SRIVASTAVA, L.S., 14.209
STEADMAN, P., 14.65
STEELE, P.A., 13.207
STEINER, H., 14.185
STEPIEN, H., 13.75
SUZUKI, K., 13.83
SWARTZ, K.J., 14.197
SZKUDLINSKI, M., 13.171

T

TAKAHASHI, R., 13.103
TAKAMATSU, Y., 13.147
TAKEDA, K., 14.225
TAKITA, M., 13.71
TÉLÉMAQUE, S., 13.263
THOMAS, K.L., 13.191

TIPPINS, J.R., **13**.95
TOUSIGNANT, C., **13**.263, **14**.275
TURNER, C.A., **13**.207

U

UMEDA, Y., **14**.237

V

VALJAKKA, A., **14**.1
VALLOTTON, M.B., **14**.111
VAN REE, J.M., **14**.71, **14**.129
VARGAS, M.-A., **14**.191
VÀZQUEZ, R., **13**.115
VEENSTRA, J.A., **14**.145
VERGONI, A.V., **14**.93
VICKROY, T.W., **13**.43
VINCENT, J.D., **14**.253

W

WARDEH, G., **14**.99
WATERS, P.E., **14**.219
WIEGANT, V.M., **14**.71
WILBER, J.F., **13**.65, **13**.221, **14**.185
WILCOX, J.N., **14**.77
WILK, S., **14**.191
WILLIS, S., **13**.253
WOLF, G.C., **13**.65
WOLTERINK, G., **14**.129
WONG, S.C., **13**.197

Y

YAMADA, M., **13**.221
YAMATSU, K., **13**.277
YASHPAL, K., **14**.21
YLINEN, A., **13**.9
YOKOSAWA, H., **14**.31, **14**.177
YOSHIKAWA, T., **13**.103
YOUNG, W.S. III, **13**.165, **13**.271
YUFU, N., **13**.285

Z

ZANNI, M., **13**.23
ZELAZOWSKI, P., **13**.75
ZEREK-MELEN, G., **13**.171
ZHOU, H.-L., **14**.161
ZIMMERMAN, E.A., **14**.137